Regulation Lags as AI-Driven Biotech Breakthroughs Redefine Risk
TL;DR
AI-enabled biotechnology is accelerating advances such as AI-designed bacteriophages, CRISPR editing, and synthetic biology, bringing major benefits but also novel, hard-to-predict risks. Regulators struggle because laws were built around separate technologies, not convergent capabilities, requiring flexible, risk-based governance that can distinguish low- from high-risk activities while enabling useful research. Case studies from New Zealand, Australia, the US, and the EU show different approaches and gaps, illustrating that the goal is balance between innovation and precaution without stifling advancement.
- The use of AI in biotechnology is changing faster than the rules governing either technology The Conversation
- Opinion | AI can design new viruses. That’s not as scary as it sounds. The Washington Post
- AI-created bacteriophage overcame resistant bacterial strains, but experts emphasize need for safeguards CIDRAP
- Scientists have designed a functioning virus from scratch using AI. What you need to know Medical Xpress
- Scientists use AI to create viruses not found in nature with medicinal potential The Jerusalem Post
Want the full story? Read the original reporting
Read on The Conversation